224 related articles for article (PubMed ID: 20049704)
21. Hydrogen sulfide inhibits hypoxia- but not anoxia-induced hypoxia-inducible factor 1 activation in a von hippel-lindau- and mitochondria-dependent manner.
Kai S; Tanaka T; Daijo H; Harada H; Kishimoto S; Suzuki K; Takabuchi S; Takenaga K; Fukuda K; Hirota K
Antioxid Redox Signal; 2012 Feb; 16(3):203-16. PubMed ID: 22004513
[TBL] [Abstract][Full Text] [Related]
22. Gramicidin A blocks tumor growth and angiogenesis through inhibition of hypoxia-inducible factor in renal cell carcinoma.
David JM; Owens TA; Inge LJ; Bremner RM; Rajasekaran AK
Mol Cancer Ther; 2014 Apr; 13(4):788-99. PubMed ID: 24493697
[TBL] [Abstract][Full Text] [Related]
23. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway.
Carroll VA; Ashcroft M
Cancer Res; 2006 Jun; 66(12):6264-70. PubMed ID: 16778202
[TBL] [Abstract][Full Text] [Related]
24. The HIF and other quandaries in VHL disease.
Tarade D; Ohh M
Oncogene; 2018 Jan; 37(2):139-147. PubMed ID: 28925400
[TBL] [Abstract][Full Text] [Related]
25. The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma.
Maranchie JK; Vasselli JR; Riss J; Bonifacino JS; Linehan WM; Klausner RD
Cancer Cell; 2002 Apr; 1(3):247-55. PubMed ID: 12086861
[TBL] [Abstract][Full Text] [Related]
26. Targeting renal cell carcinoma with a HIF-2 antagonist.
Chen W; Hill H; Christie A; Kim MS; Holloman E; Pavia-Jimenez A; Homayoun F; Ma Y; Patel N; Yell P; Hao G; Yousuf Q; Joyce A; Pedrosa I; Geiger H; Zhang H; Chang J; Gardner KH; Bruick RK; Reeves C; Hwang TH; Courtney K; Frenkel E; Sun X; Zojwalla N; Wong T; Rizzi JP; Wallace EM; Josey JA; Xie Y; Xie XJ; Kapur P; McKay RM; Brugarolas J
Nature; 2016 Nov; 539(7627):112-117. PubMed ID: 27595394
[TBL] [Abstract][Full Text] [Related]
27. The VHL/HIF oxygen-sensing pathway and its relevance to kidney disease.
Haase VH
Kidney Int; 2006 Apr; 69(8):1302-7. PubMed ID: 16531988
[TBL] [Abstract][Full Text] [Related]
28. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.
Clifford SC; Astuti D; Hooper L; Maxwell PH; Ratcliffe PJ; Maher ER
Oncogene; 2001 Aug; 20(36):5067-74. PubMed ID: 11526493
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors.
Zimmer M; Doucette D; Siddiqui N; Iliopoulos O
Mol Cancer Res; 2004 Feb; 2(2):89-95. PubMed ID: 14985465
[TBL] [Abstract][Full Text] [Related]
30. Calcineurin promotes hypoxia-inducible factor 1alpha expression by dephosphorylating RACK1 and blocking RACK1 dimerization.
Liu YV; Hubbi ME; Pan F; McDonald KR; Mansharamani M; Cole RN; Liu JO; Semenza GL
J Biol Chem; 2007 Dec; 282(51):37064-73. PubMed ID: 17965024
[TBL] [Abstract][Full Text] [Related]
31. Hypoxia-inducible factor 1α mediates the down-regulation of superoxide dismutase 2 in von Hippel-Lindau deficient renal clear cell carcinoma.
Gao YH; Li CX; Shen SM; Li H; Chen GQ; Wei Q; Wang LS
Biochem Biophys Res Commun; 2013 May; 435(1):46-51. PubMed ID: 23611775
[TBL] [Abstract][Full Text] [Related]
32. Collagen matrix assembly is driven by the interaction of von Hippel-Lindau tumor suppressor protein with hydroxylated collagen IV alpha 2.
Kurban G; Duplan E; Ramlal N; Hudon V; Sado Y; Ninomiya Y; Pause A
Oncogene; 2008 Feb; 27(7):1004-12. PubMed ID: 17700531
[TBL] [Abstract][Full Text] [Related]
33. Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma.
Petrella BL; Lohi J; Brinckerhoff CE
Oncogene; 2005 Feb; 24(6):1043-52. PubMed ID: 15592504
[TBL] [Abstract][Full Text] [Related]
34. iASPP is essential for HIF-1α stabilization to promote angiogenesis and glycolysis via attenuating VHL-mediated protein degradation.
Zhao D; Zheng S; Wang X; Liu H; Zhao K; Li L; Hu Y
Oncogene; 2022 Mar; 41(13):1944-1958. PubMed ID: 35169254
[TBL] [Abstract][Full Text] [Related]
35. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.
Na X; Wu G; Ryan CK; Schoen SR; di'Santagnese PA; Messing EM
J Urol; 2003 Aug; 170(2 Pt 1):588-92. PubMed ID: 12853836
[TBL] [Abstract][Full Text] [Related]
36. Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells.
Gunaratnam L; Morley M; Franovic A; de Paulsen N; Mekhail K; Parolin DA; Nakamura E; Lorimer IA; Lee S
J Biol Chem; 2003 Nov; 278(45):44966-74. PubMed ID: 12944410
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of the hypoxia-inducible factor pathway by a G-quadruplex binding small molecule.
Welsh SJ; Dale AG; Lombardo CM; Valentine H; de la Fuente M; Schatzlein A; Neidle S
Sci Rep; 2013 Sep; 3():2799. PubMed ID: 24165797
[TBL] [Abstract][Full Text] [Related]
38. Prognostic Value of the VHL, HIF-1α, and VEGF Signaling Pathway and Associated MAPK (ERK1/2 and ERK5) Pathways in Clear-Cell Renal Cell Carcinoma. A Long-Term Study.
Salinas-Sánchez AS; Serrano-Oviedo L; Nam-Cha SY; Roche-Losada O; Sánchez-Prieto R; Giménez-Bachs JM
Clin Genitourin Cancer; 2017 Dec; 15(6):e923-e933. PubMed ID: 28624320
[TBL] [Abstract][Full Text] [Related]
39. Identification of Ror2 as a hypoxia-inducible factor target in von Hippel-Lindau-associated renal cell carcinoma.
Wright TM; Rathmell WK
J Biol Chem; 2010 Apr; 285(17):12916-24. PubMed ID: 20185829
[TBL] [Abstract][Full Text] [Related]
40. The VHL tumor suppressor and HIF: insights from genetic studies in mice.
Kapitsinou PP; Haase VH
Cell Death Differ; 2008 Apr; 15(4):650-9. PubMed ID: 18219317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
